109 related articles for article (PubMed ID: 3150222)
1. BFM program in treatment of childhood ALL--statistical evaluation of prognostic factors.
Derulska D; Rokicka-Milewska R; Lewicki Z
Acta Paediatr Jpn; 1988 Jun; 30(3):359-67. PubMed ID: 3150222
[No Abstract] [Full Text] [Related]
2. Acute lymphoblastic leukaemia therapy in Poland. A report from the Polish Children's Leukaemia/Lymphoma Study Group.
Radwańska U; Michalewska D; Armata J; Balwierz W; Bogusławska-Jaworska J; Cyklis R; Derulska D; Kołecki P; Lastowska M; Newecka-Samól T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):199-210. PubMed ID: 2475398
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute lymphoblastic leukemia: protocol Fralle 83-85.
Schaison G; Olive D; Leverger G; Vannier JP; de Lumley L; Bancillon A; Cornu G
Haematol Blood Transfus; 1990; 33():467-72. PubMed ID: 2182438
[No Abstract] [Full Text] [Related]
4. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
5. Treatment of childhood acute lymphoblastic leukaemia with the BFM regimen.
Kudva GC; Chandy M; Raghupathy P; Dennison D; Srivastava A; Bhushan V; Singh R
Indian J Cancer; 1994 Jun; 31(2):78-85. PubMed ID: 7927453
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.
Ludwig WD; Harbott J; Bartram CR; Komischke B; Sperling C; Teichmann JV; Seibt-Jung H; Notter M; Odenwald E; Nehmer A
Recent Results Cancer Res; 1993; 131():269-82. PubMed ID: 8210646
[No Abstract] [Full Text] [Related]
7. Results and significance of six randomized trials in four consecutive ALL-BFM studies.
Riehm H; Gadner H; Henze G; Kornhuber B; Lampert F; Niethammer D; Reiter A; Schellong G
Haematol Blood Transfus; 1990; 33():439-50. PubMed ID: 2182435
[No Abstract] [Full Text] [Related]
8. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?
Styczynski J; Wysocki M
J Clin Oncol; 2004 Mar; 22(5):963-4. PubMed ID: 14990658
[No Abstract] [Full Text] [Related]
9. [21 years in the treatment of acute lymphoblastic leukemias in children (1967-1987)].
Ortega JJ; Javier G; Olivé T; Montagut JM
Sangre (Barc); 1988 Oct; 33(5):372-82. PubMed ID: 3073534
[No Abstract] [Full Text] [Related]
10. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
Conter V; Aricò M; Basso G; Biondi A; Barisone E; Messina C; Parasole R; De Rossi G; Locatelli F; Pession A; Santoro N; Micalizzi C; Citterio M; Rizzari C; Silvestri D; Rondelli R; Lo Nigro L; Ziino O; Testi AM; Masera G; Valsecchi MG;
Leukemia; 2010 Feb; 24(2):255-64. PubMed ID: 20016536
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
[TBL] [Abstract][Full Text] [Related]
12. DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials.
Hiddemann W; Harbott J; Ludwig WD; Ritter J; Nehmer A; Reiter A; Kolkmeyer A; Laing T; Riehm H
Recent Results Cancer Res; 1993; 131():113-21. PubMed ID: 8210632
[No Abstract] [Full Text] [Related]
13. Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988).
Veerman AJ; Hählen K; Kamps WA; Vanleeuwen EF; de Vaan GA; Vanwering ER; Vanderdoes-Vandenberg A; Solbu G; Suciu S
Haematol Blood Transfus; 1990; 33():473-7. PubMed ID: 2182439
[No Abstract] [Full Text] [Related]
14. Acute lymphoblastic leukemia: current treatment concepts.
Arya LS
Indian Pediatr; 2000 Apr; 37(4):397-406. PubMed ID: 10781233
[No Abstract] [Full Text] [Related]
15. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
16. Results of acute lymphoblastic leukemia therapy in childhood: GDR-experiences 1981-1987.
Zintl F; Malke H; Reimann M; Dörffel W; Domula M; Eggers G; Exadaktylos P; Kotte W; Krause I; Kunert W
Haematol Blood Transfus; 1990; 33():478-82. PubMed ID: 2182440
[No Abstract] [Full Text] [Related]
17. [Acute lymphatic leukemia. Risk factors, chemotherapy/radiotherapy].
Hoelzer D
Internist (Berl); 1993 Jun; 34(6):526-33. PubMed ID: 8335442
[No Abstract] [Full Text] [Related]
18. [Treatment of acute lymphoblastic leukemia in children according to the Berlin-Frankfurt-Münster Program].
Rumiantsev AG; Samochatova EV; Tabet Khamdan
Pediatriia; 1991; (11):58-63. PubMed ID: 1766743
[No Abstract] [Full Text] [Related]
19. [Preliminary evaluation of the treatment of recurrences of acute lymphoblastic leukemia by the BFM (Henze) method].
Ochocka M; Zelenay E
Pediatr Pol; 1988 Nov; 63(11):716-22. PubMed ID: 3253658
[No Abstract] [Full Text] [Related]
20. [Effect of prognostic factors on the course of acute lymphoblastic leukemia in children].
Rokicka-Milewska R; Derulska D; Lewicki Z
Pediatr Pol; 1988 Nov; 63(11):703-15. PubMed ID: 3253657
[No Abstract] [Full Text] [Related]
[Next] [New Search]